Explore

Rapid Read Rapid Read
GlycanAge to Host Conference on Inflammaging Research, Aiming for Clinical Integration

GlycanAge to Host Conference on Inflammaging Research, Aiming for Clinical Integration

GlycanAge, a company specializing in biological age testing through glycan analysis, is organizing a significant conference in Dubrovnik, Croatia, this June. The event marks 25 years of research into 'inflammaging,' a concept that links chronic low-grade inflammation to biological aging and age-related diseases. The conference, co-organized with the Mayo Clinic as part of the International Society for Applied Biological Sciences (ISABS) series, will feature leading academics and clinicians. The scientific program will be headlined by Prof. Dr. Claudio Franceschi, who coined the term 'inflammaging.' GlycanAge aims to move chronic-inflammation testing into routine clinical practice, highlighting the potential of glycan-based markers to predict diseases like diabetes and heart conditions up to a decade before symptoms appear.
Trendline Trendline
Caris Life Sciences Introduces AI-Powered Test for Breast Cancer Recurrence Risk

Caris Life Sciences Introduces AI-Powered Test for Breast Cancer Recurrence Risk

Caris Life Sciences Introduces AI-Powered Test for Breast Cancer Recurrence Risk
Rapid Read Rapid Read
Castle Biosciences' TissueCypher Test Enhances Risk Management in Barrett's Esophagus

Castle Biosciences' TissueCypher Test Enhances Risk Management in Barrett's Esophagus

Castle Biosciences, Inc. has announced new data from Mayo Clinic researchers demonstrating the effectiveness of the TissueCypher test in improving risk stratification for patients with Barrett's esophagus. Presented at Digestive Disease Week 2026, the findings show that the test can predict a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma. The study revealed that the test influenced changes in surveillance intervals for over half of the patients, aligning with the test's risk classification. This molecular test provides more accurate risk assessments compared to traditional histopathology, allowing for more personalized patient management.
Trendline Trendline
Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies

Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies

Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies
Trendline Trendline
MRD Testing Revolutionizes Breast Cancer Risk Assessment

MRD Testing Revolutionizes Breast Cancer Risk Assessment

MRD Testing Revolutionizes Breast Cancer Risk Assessment
Trendline Trendline
Armatus Bio Develops Potency Assay Platform for Gene Silencing Therapies

Armatus Bio Develops Potency Assay Platform for Gene Silencing Therapies

Armatus Bio Develops Potency Assay Platform for Gene Silencing Therapies
Rapid Read Rapid Read
North Metro Fire Rescue Implements New Technology to Enhance Patient Monitoring

North Metro Fire Rescue Implements New Technology to Enhance Patient Monitoring

The North Metro Fire Department has started using new technology to improve patient monitoring during emergency calls. This initiative aims to enhance the department's ability to provide timely and effective care to patients in critical situations. The technology allows for better tracking of patient conditions, potentially leading to improved outcomes and increased efficiency in emergency response.
Rapid Read Rapid Read
Cairn Surgical's Breast Cancer Locator System Shows Promising Trial Results

Cairn Surgical's Breast Cancer Locator System Shows Promising Trial Results

Cairn Surgical, Inc. has announced the successful results of a pivotal trial for its Breast Cancer Locator (BCL) System, which aims to enhance precision in breast cancer surgeries. The trial demonstrated a significant reduction in positive margin rates and re-excision rates compared to conventional wire localization methods. The BCL System provides intraoperative guidance by offering detailed information about tumor shape, size, and location, derived from supine MRI scans. These results were presented at the American Society of Breast Surgeons' annual meeting, highlighting the system's potential to improve surgical outcomes for breast cancer patients.
Trendline Trendline
Scientists Discover Molecule for Weight Loss Without Bone Damage

Scientists Discover Molecule for Weight Loss Without Bone Damage

Scientists Discover Molecule for Weight Loss Without Bone Damage
Trendline Trendline
Foundation Medicine and Fulgent Genetics Launch Pharmacogenetic Testing for Cancer Treatment

Foundation Medicine and Fulgent Genetics Launch Pharmacogenetic Testing for Cancer Treatment

Foundation Medicine and Fulgent Genetics Launch Pharmacogenetic Testing for Cancer Treatment
Rapid Read Rapid Read
GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in U.S. Adults

GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in U.S. Adults

GLP-1 drugs, initially developed for diabetes treatment, have become widely used in the U.S. for weight loss, with an estimated 15 million American adults having used them in the past year. These medications, including semaglutide and tirzepatide, are marketed under names like Ozempic and Mounjaro. While they have contributed to a decrease in obesity rates, a new study published in Science Progress highlights a potential side effect: hair loss. The study found that hair loss was more prevalent among users taking higher doses for rapid weight loss. Dr. Paradi Mirmirani from the University of California San Francisco noted that while hair shedding can occur, it is usually temporary and manageable with proper nutrition and weight management. The study suggests that the hair loss may be linked to malnutrition due to reduced appetite, a side effect of the drugs.
Rapid Read Rapid Read
Study Reveals Immune Cells Retain 'Memory' of Obesity After Weight Loss

Study Reveals Immune Cells Retain 'Memory' of Obesity After Weight Loss

A new study has found that certain immune cells retain a 'memory' of obesity, which can persist long after weight loss. This discovery suggests that even after losing weight, individuals may remain at an elevated risk for obesity-related illnesses due to epigenetic changes in immune cells. The study, conducted over a decade, identified DNA methylation as a key mechanism by which immune cells remember past obesity, potentially influencing long-term health outcomes. This research highlights the complex relationship between obesity, immune function, and disease risk.